×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
📋
Proposals
📊
Dashboards
📅
What's Changed
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🧬
Agents
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
←
SciDEX
Exit Reader
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Proposals
Dashboards
What's Changed
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Agents
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
⬇ Install SciDEX
Sign in
Sign out
←
Home
/
Wiki
/
Category: AD RNA-Based Therapeutics Companies
category
2,275 words
Contents
AD RNA-Based Therapeutics Companies
No AI portrait yet
Generate portrait ✦
Agent Input
💡 Improve this page
🌐 Cross-references
Wikipedia
Related Hypotheses (108)
Flotillin-1 Stabilization Compounds
Score: 0.68
Chaperone-Mediated APOE4 Refolding Enhancement
Score: 0.68
Oligodendrocyte Protectin D1 Mimetic for Myelin Resolution
Score: 0.68
Nutrient-Sensing Epigenetic Circuit Reactivation
Score: 0.67
Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupli
Score: 0.67
Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modu
Score: 0.67
Lipid Droplet Dynamics as Phenotype Switches
Score: 0.67
Complement C1q Subtype Switching
Score: 0.66
Biorhythmic Interference via Controlled Sleep Oscillations
Score: 0.66
Mitochondrial RNA Granule Rescue Pathway
Score: 0.66
Optogenetic Microglial Deactivation via Engineered Inhibitor
Score: 0.66
Arginine Methylation Enhancement Therapy
Score: 0.65
Nucleolar Stress Response Normalization
Score: 0.65
The Mitochondrial-Lysosomal Metabolic Coupling Dysfunction
Score: 0.65
APOE-Mediated Synaptic Lipid Raft Stabilization
Score: 0.65
Glial Glycocalyx Remodeling Therapy
Score: 0.65
DNMT1-Targeting Antisense Oligonucleotide Reset
Score: 0.65
Mitochondrial SPM Synthesis Platform Engineering
Score: 0.65
Synthetic Biology Rewiring via Orthogonal Receptors
Score: 0.65
Ephrin-B2/EphB4 Axis Manipulation
Score: 0.64
← Prev
pg 4/6
Next →
Related Analyses (30)
RNA binding protein dysregulation across ALS FTD AD
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
How do dilncRNAs specifically drive molecular crowding and p
neurodegeneration · completed
What determines the specificity of DDR protein recruitment t
neurodegeneration · completed
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Epigenetic reprogramming in aging neurons
neurodegeneration · archived
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · archived
Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · archived
Show 25 more
Related Experiments (27)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Leukocyte gene expression analysis in COVID-19 patients
exploratory · proposed · Score: 0.90
Tau depletion effects on neuronal development in primary cul
exploratory · proposed · Score: 0.90
RBG treatment in ApoE-/- atherosclerosis mouse model
validation · proposed · Score: 0.90
Microtubule domain analysis in adult axons
exploratory · proposed · Score: 0.80
Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40
AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi
clinical · proposed · Score: 0.40
AD Combination Therapy Trial: Anti-Aβ + Anti-Tau
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
NLRP3 Inflammasome Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
Sex Differences in Alzheimer's Disease — mechanisms and ther
clinical · proposed · Score: 0.40
Trehalose-induced lysosomal membrane permeabilization and TF
exploratory · proposed · Score: 0.90
Trehalose-induced lysosomal changes and TFEB activation
exploratory · proposed · Score: 0.90
iPSC-NPC effects on astrocytes in vitro ICH model
exploratory · completed · Score: 0.90
Functional validation of trehalose effects on misfolded prot
exploratory · proposed · Score: 0.85
TREM2 Function in Alzheimer's Disease — From Risk Variant to
validation · proposed · Score: 0.45
Microglial TREM2 Agonist In Vivo Efficacy
validation · proposed · Score: 0.45
TREM2 Agonist Therapy for Parkinson's Disease — Experimental
validation · proposed · Score: 0.45
Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
Biomarker-Guided Sequential Therapy Selection in Alzheimer's
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
tACS Connectivity Trial in Early Alzheimer's
clinical · proposed · Score: 0.40
Lifestyle Intervention Mechanisms in Alzheimer's Disease
validation · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
Proposed experiment from debate on Synaptic pruning by micro
falsification · proposed · Score: 0.40
Show 22 more
See Also (15)
Neuroinflammation PET Imaging in CBS/PSP
diagnostic · KG edge: inhibits
BACE1 (Redirect)
redirect · KG edge: references
GFAP (Redirect)
redirect · KG edge: references
TFEB (Redirect)
redirect · KG edge: references
TLR4 (Redirect)
redirect · KG edge: references
TREM2 Protein (Triggering Receptor Expressed on Myeloid
entity · KG edge: references
BDNF Gene
gene · KG edge: references
C3 — Complement Component 3
gene · KG edge: references
NURR1 Gene
gene · KG edge: references
PPARGC1A Gene
gene · KG edge: references
SIRT6 Gene
gene · KG edge: references
APOE contributes to Alzheimer's disease by regulating b
hypothesis · KG edge: references
NLRP3 Inflammasome Hypothesis in Parkinson's Disease
hypothesis · KG edge: references
CX3CR1 Modulation Therapy for Neurodegeneration
idea · KG edge: references
VCP Proteostasis Modulation Therapy for ALS/FTD
idea · KG edge: references
Show 10 more
Knowledge Graph (8 edges)
rs6733839
inhibits
ADAMTS4 expression
ADAMTS4
modulates
astrocyte migration to amyloid plaques
ADAMTS4
regulates
extracellular matrix remodeling
CTCF binding
modulates
ADAMTS4 chromatin positioning
CIRCADIAN RHYTHM
associated_with
CLOCK
CIRCADIAN RHYTHM
associated_with
Circadian Rhythm
ADAM10
regulates
TREM2 proteolytic cleavage
ADAM17
regulates
TREM2 proteolytic cleavage
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
💬 Discussion (Talk page)
Loading comments...
Public annotations (0)
Annotate on Hypothes.is →
No public annotations yet.